Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk by Langholm, Lasse L. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium
Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk
Langholm, Lasse L.; Ronnow, Sarah Rank; Sand, Jannie M. B.; Leeming, Diana Julie; Tal-
Singer, Ruth; Miller, Bruce E.; Vestbo, Jorgen; Karsdal, Morten A.; Manon-Jensen, Tina
Published in:
International Journal of Chronic Obstructive Pulmonary Disease
DOI:
10.2147/COPD.S235673
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Langholm, L. L., Ronnow, S. R., Sand, J. M. B., Leeming, D. J., Tal-Singer, R., Miller, B. E., ... Manon-Jensen,
T. (2020). Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is
Associated with Emphysema, Exacerbations and Elevated Mortality Risk. International Journal of Chronic
Obstructive Pulmonary Disease, 15, 543-552. https://doi.org/10.2147/COPD.S235673
Download date: 10. Sep. 2020
OR I G I N A L R E S E A R C H
Increased von Willebrand Factor Processing in
COPD, Reflecting Lung Epithelium Damage, Is
Associated with Emphysema, Exacerbations and
Elevated Mortality Risk
This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease
Lasse L Langholm 1,2
Sarah Rank Rønnow 1,3
Jannie MB Sand1
Diana Julie Leeming1
Ruth Tal-Singer 4
Bruce E Miller 4
Jørgen Vestbo 5
Morten A Karsdal1
Tina Manon-Jensen1
1Nordic Bioscience A/S, Herlev,
Denmark; 2University of Copenhagen,
Faculty of Health and Medical Sciences,
Department of Biomedical Sciences,
Copenhagen, Denmark; 3University of
Southern Denmark, The Faculty of
Health Science, Odense, Denmark;
4Respiratory Medical Innovation, Value
Evidence & Outcomes, GSK R&D,
Collegeville, PA, USA; 5Division of
Infection, Immunity and Respiratory
Medicine, University of Manchester, and
Manchester University NHS Foundation
Trust, Manchester, UK
Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic
inflammation and lung tissue deterioration. Given the high vascularity of the lung, von
Willebrand factor (VWF), a central component of wound healing initiation, has previously
been assessed in COPD. VWF processing, which is crucial for regulating the primary
response of wound healing, has not been assessed directly. Therefore, this study aimed to
characterize wound healing initiation in COPD using dynamic VWF-processing biomarkers
and to evaluate how these relate to disease severity and mortality.
Methods: A cross-sectional analysis of plasma samples from the ECLIPSE study collected
at year 1 from moderate to very severe COPD subjects (GOLD 2–4, n=984) was performed.
We applied competitive neo-epitope ELISAs specifically targeting the formation of and
ADAMTS13-processed form of VWF, VWF-N and VWF-A, respectively.
Results: VWF-A and VWF-N were significantly increased (VWF-N, p=0.01; VWF-A,
p=0.0001) in plasma of symptomatic (mMRC score ≥2) compared to asymptomatic/mild
symptomatic COPD subjects. Increased VWF-N and VWF-A levels were specifically asso-
ciated with emphysema (VWF-N, p<0.0001) or prior exacerbations (VWF-A, p=0.01). When
dichotomized, high levels of both biomarkers were associated with increased risk of all-cause
mortality (VWF-N, HR 3.5; VWF-A, HR 2.64).
Conclusion: We demonstrate that changes in VWF processing were related to different
pathophysiological aspects of COPD. VWF-N relates to the chronic condition of emphy-
sema, while VWF-A was associated with the more acute events of exacerbations. This study
indicates that VWF-A and VWF-N may be relevant markers for characterization of disease
phenotype and are associated with mortality in COPD.
Study Identifier: NCT00292552; GSK study code SCO104960.
Keywords: von Willebrand factor processing, COPD, emphysema, exacerbations, increased
mortality risk
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway
obstruction and includes individuals with chronic bronchitis and/or emphysema
who may experience acute worsenings or exacerbations, which accelerate the
degeneration of lung tissue14,37 and increase mortality risk.39 An abnormal inflam-
matory response, including disruption of normal tissue repair processes and activa-
tion of wound healing, is believed to be among the underlying drivers of COPD,
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leading to small airway fibrosis.4,25,31 Subjects with COPD
present with very heterogeneous disease characteristics,1
which complicates identification of mortality predictors
and lung function decline. Identifying subjects with pro-
gressive phenotypes such as emphysema and exacerba-
tions using biomarkers reflecting inflammation and tissue
damage could be a valuable tool in assessing mortality risk
in COPD.
Protein components of the wound healing cascade and
inflammatory signaling are affected in COPD and could be
potential biomarkers to help characterize COPD pheno-
types and severity.2,11 Platelets are essential for blood
clotting during wound healing and have shown highly
increased activation in COPD.24 Furthermore, the lungs
are a major contributor to platelet biogenesis and
a reservoir for platelet-producing megakaryocytes.23 von
Willebrand factor (VWF) is an important player in platelet
activation and a biomarker of endothelial dysfunction and
inflammation in COPD.35 VWF is a large multimeric
glycoprotein that circulates in the bloodstream or is stored
in either platelet α-granules or the Weibel-Palade bodies of
endothelial cells.30,43 In response to endothelial damage,
VWF is activated by shear-stress, unfolding the multimers
and thereby facilitating platelet-tethering to damaged sub-
endothelial extracellular matrix (ECM) leading to bleeding
cessation.3,38 During VWF unfolding, a cleavage-site for
the metalloproteinase ADAMTS13 at Tyr1605-Met1606 is
exposed, resulting in cleavage and reduction of VWF
multimer size, which also regulates VWF activity.32
Notably, only in the active unfolded conformation can
ADAMTS13 cleave VWF.13,32 Both VWF and platelets
have been shown to have altered levels and activities in
inflammatory disorders,22,29 indicating a function beyond
just facilitating hemostasis. Increased VWF levels could
therefore potentially reflect the persistence of chronic
inflammation in COPD.
VWF levels and relative activity have been found to be
increased in COPD,8 but VWF-processing products
reflecting endothelial release and activation, which is the
central axis of initiation of the primary wound healing
response have, to our knowledge, not been assessed
directly in COPD subjects.
To emphasize the role that the vascular endothelium
plays in lung tissue destruction and inflammation in
COPD, we applied two biomarkers of VWF-processing
measuring VWF formation by targeting the released pro-
peptide (VWF-N) and ADAMTS13-cleaved activated
VWF (VWF-A) using neo-epitope specific monoclonal
antibodies. We hypothesized that ADAMTS13-cleaved
VWF generates a dynamic biomarker of tissue damage,
inflammation and platelet activation, while VWF-N reflect
newly released VWF into the circulation. The aim of this
study was to characterize tissue damage and hemostatic
processes in COPD, to describe how these dynamic VWF-
processing biomarkers relate to disease severity and
mortality.
Materials and Methods
The study population consisted of a cross-sectional subset
of plasma samples from the Evaluation of COPD
Longitudinally to Identify Predictive Surrogate End-
points (ECLIPSE) study collected at year 1 from moderate
to very severe COPD patients (GOLD stage 2–4, n=957)
and non-COPD controls including both smoker- (n=203)
and non-smoker-controls (n=96). The study design of
ECLIPSE (clinicaltrials.gov identifier NCT00292552;
GSK study code SCO104960) has been fully described
previously.40 In short, ECLIPSE is a non-interventional,
observational, multicentre study in patients with COPD
(n=2164) and control subjects (n=582). Participants were
monitored at specific time points during the study, which
ran for three years in total. Inclusion criteria were baseline
post-bronchodilator forced expiratory volume in
one second (FEV1) values of <80% of predicted, an
FEV1/FVC (forced vital capacity) ratio of ≤0.7 and ≥10
pack-years of previous smoking history. The controls were
divided into a non-smoker and smoker control group
defined by less than or more than 10 pack-years of smok-
ing history, respectively, in addition to normal lung
function.40 In our analyses, we used biomarker and other
clinically relevant data collected at baseline and year 1, as
well as follow-up data on mortality.
Heparin plasma samples were prepared from whole
blood collected by venipuncture in vacutainer tubes from
fasting participants. Plasma was obtained by centrifuging
the samples for 10–15 min at 2000 x g, before storage at
−80°C until analyzed.
Competitive enzyme-linked immunosorbent assay
(ELISA) format was used to assess protein fragments of
VWF release (VWF-N) and ADAMTS13-processing
(VWF-A) using neo-epitope specific mouse monoclonal
antibodies28 (Nordic Bioscience A/S, Herlev, Denmark).
The term neo-epitope defines a specific amino acid
sequence generated by specific proteolytic cleavage. The
antibodies are specific for only the proteolytically pro-
cessed protein form. Briefly, the assays were performed
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on a 96-well streptavidin plate coated with 100µL of
dissolved specific biotinylated synthetic peptide in an opti-
mized coating buffer, incubated for 30 min at 20°C. 20 µL
of sample or standard peptide diluted in incubation buffer
were applied to the plate followed by 100 µL of antibody
solution, incubated overnight (20 hrs) at 4°C with shaking.
Subsequently, 100 µL of horseradish peroxidase (HRP)
labeled secondary anti-mouse antibody was added and
incubated for 1 hr at 20°C. Finally, the plates were incu-
bated with 100 µL of tetramethylbenzidine (TMB) for 15
min at 20°C in the dark. The HRP reaction was stopped by
adding 100 µL of stopping solution (1% H2SO4). All
steps, aside from the TMB to stop-solution, were followed
by a plate wash cycle to remove unbound and excess
reagents. Plates were read in a SpectraMax M5
(Molecular Devices, CA, USA) at 450nm with 650nm as
a reference.
We included analyses of CRP, previously measured in
the ECLIPSE study.41 Prospective analyses were based on
follow-up on all-cause mortality (n=30) two years post
blood-sampling (to day 1080 from study start).
Statistics
D’Agostino-Pearson testing found biomarker data not to
be normally distributed; therefore, the statistical analyses
were performed by non-parametric methods. One-way
ANOVA and chi-squared test were used to evaluate patient
demographics and clinical biomarkers. Mann–Whitney
t-test and Kruskal–Wallis testing were applied to compare
biomarker levels between groups. ROC curve analysis was
utilized to define biomarker cut-offs from Youden Index
criterion based on mortality data and survival curves were
displayed using Kaplan-Meier plotting. Cox proportional
hazard regression analysis was used to estimate hazard
ratios (HR) per 1 SD change in biomarker for predicting
mortality. HR was adjusted for the following confounders
of mortality identified from univariate analysis: age, smok-
ing history, high-sensitivity C-reactive protein (hsCRP),
6 min walking distance (6MWD), dyspnea scale
(mMRC) and prior hospitalizations. The software used
was GraphPad Prism version 7.00 for Windows
(GraphPad Software, La Jolla California USA) and
MedCalc Statistical Software version 14.8.1 (MedCalc
Software bvba, Ostend, Belgium). A p-value <0.05 was
considered statistically significant. Data presented as med-
ian + 95% Confidence interval (CI), unless stated
otherwise.
Results
Mean age, BMI and percent of predicted FEV1 (FEV1%
predicted) for the COPD subjects were 63.1, 26.8 and
50.4, respectively, thereby being significantly older than
the controls and having a lower BMI than the non-smoker
controls. There were also significantly higher percentage
of men in the COPD group. The FEV1% predicted con-
firmed their highly decreased lung capacity (Table 1).
Table 1 Participant Demographics
COPD Smoker Controls Non-Smoker Controls P-value
n 957 203 96
Sex, M (%) 63,3 36,5 51,0 *P < 0.001
Age, years 64 (40–75) 53 (40–74) 59 (40–73) †P < 0.001
BMI, kg/m2 26.2 (12.1–55.7) 26.0 (17.8–39.3) 27.8 (18.8–44.4) †P = 0.028
FEV1 baseline, L 1.36 (0.39–3.32) 3.06 (1.66–5.12) 3.11 (1.82–5.14)
†P < 0.001
FEV1, L 1.32 (0.36–3.56) 2.95 (1.47–5.28) 3.07 (1.75–5.20)
†P < 0.001
FEV1% predicted, L 50.0 (14.9–96.7) 106.1 (71.6–150.5) 114.1 (69.4–152.4)
†P < 0.001
%LAA 14.3 (0.18–54.8) 1.52 (0.08–14.4) NA †P < 0.001
Current smokers 359 (37.5%) NA NA *P = 0.80
Smoking history, pack years 43.0 (6–220) 26.0 (10.0–230.0) 0 (0–8.0) †P < 0.001
mMRC 1.0 (0.0–4.0) 0 (0.0–3.0) 0 (0.0–2.0) †P < 0.001
GOLD Stage (%)
II (n= 471) 40.7 NA NA
III (n=389) 49.2
IV (n=97) 10.1
Notes: Data are shown as median (min-max or %). FEV1, Forced expiratory volume in one second (post-bronchodilator); %LAA, percent low attenuation area on chest
computed tomography; mMRC, modified medical research council (dyspnea scale); GOLD, Global initiative for chronic Obstructive Lung Disease; NA, not applicable (not
measured or less than 5 patients). FEV1/%LAA is from year 1, while all other data are from baseline. Statistical analyses performed to determine P-values between groups by
*Chi-squared test or †One-way ANOVA analysis.
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Plasma VWF-N and VWF-Awere significantly elevated
in COPD subjects compared to smoker controls (p<0.05)
but not compared to non-smoker controls (Figure 1A). Both
biomarkers proved to be significantly elevated in COPD
subjects compared to the combined control groups
(VWF-N, VWF-A, p=0.01), data not shown.
We wanted to investigate disease activity of COPD and
how this relates to VWF processing, firstly by addressing
symptomatic COPD. We divided the COPD subjects into
symptomatic and asymptomatic/mild subjects, based on
a modified Medical Research Council (mMRC) dyspnea
scale cut off of two as previously described in the GOLD
guidelines.42 Both VWF biomarkers were significantly
increased in symptomatic (mMRC ≥2) compared to
asymptomatic/mild (mMRC ≥2) COPD subjects, with
VWF-A being the more statistically significant of the
two (VWF-N, p=0.0002; VWF-A, p<0.0001; Figure 1B).
Next, we sought to investigate if there was a specific
VWF-processing profile between different underlying
symptoms or subtypes of COPD, such as emphysema
non-smoker cont.
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Figure 1 VWF processing was increased in COPD and symptomatic disease. (A) VWF-N and VWF-A were significantly increased in COPD subjects (n=957) compared to
smoker controls (n=203), but not non-smoker controls (n=96). (B) Both VWF-N and VWF-A were significantly increased in symptomatic (mMRC ≥2) COPD subjects
(n=458) compared to non-symptomatic/mild COPD (n=462). Data presented as median + 95% CI. *p<0.05, ***p<0.001.
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and exacerbations. Emphysema was defined as low
attenuation area of −950 Hounsfield units of more than
10% (%LAA) on chest computed tomography,41 while
exacerbations were self-reported events within the year
prior to the blood sampling used for our biomarker mea-
surements. Twenty-four percent of patients with GOLD
stage 2, 32% with stage 3 and 44% in stage 4 were
considered frequent exacerbators, having had two or
more exacerbations within the year prior to sampling.20
We observed increased VWF-A and not VWF-N levels in
subjects who had experienced exacerbations (VWF-A,
p=0.009; VWF-N, p=0.87; Figure 2A), while for emphy-
sematous subjects, only VWF-N levels were significantly
elevated (p<0.0001) while VWF-A levels were unchanged
(p=0.09) (Figure 2B).
Knowing that emphysema and exacerbations are
related to decreasing survival rates, we wanted to investi-
gate if VWF processing was associated with risk of mor-
tality. Both VWF biomarkers were significantly increased
in subjects that died (n=30) within the follow-up period
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Figure 2 VWF processing was different between subjects with emphysema and exacerbations. (A) VWF-A but not VWF-N was increased in COPD subjects who suffered
from one or more exacerbations within the previous year (n=522), compared to the no exacerbation group (n=418). (B) VWF-N but not VWF-A is increased in COPD
subjects with emphysema (n=584) compared to non-emphysematous subjects (n=310). Data presented as median + 95% CI. *p<0.05, ***p<0.001.
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(VWF-N, p=0.0001; VWF-A, p=0.0056; Figure 3A). We
then wanted to define a cut off for high VWF levels,
associated with increased mortality. We dichotomized the
VWF biomarkers using ROC curve analysis of mortality
data, resulting in a Youden index criterion of 6.7 ng/mL
and 9.7 ng/mL for VWF-N and VWF-A, respectively.
Using these cutoffs to define high versus low levels of
VWF-N and VWF-A, we analyzed survival times using
Kaplan-Meier survival curves (Figure 3B).
To address this further we investigated if the biomar-
kers were independently associated with mortality, consid-
ering possible confounding factors of mortality using cox
proportional hazards regression. We identified age, 6 min
walking distance (6 MWD), hsCRP, mMRC, prior hospi-
talizations and current smoking status as confounders to
all-cause mortality (Table 2). Adjusting for these covari-
ates we could define an adjusted hazard ratio of 1.214 per
1 SD increase in biomarker levels (95% CI 1.089; 1.352)
for VWF-N (p<0.001) and 1.26 per 1 SD for VWF-A
(95% CI 0.963; 1.652) (p=0.018) (Table 3).
Evaluating the dichotomized biomarker data we could
devise the best cox regression models including all
confounders. The resulting models (adjusted for significant
confounders) indicate that high levels of VWF-N (>6.7 ng/
mL) and VWF-A (>9.7 ng/mL) were independently asso-
ciated with mortality with an HR of 3.5 (95% CI 1.57;
7.79) and 2.64 (95% CI 1.18; 5.91), respectively (Table 3).
Discussion
In this study, we addressed the role of wound healing
initiation in COPD pathology, and found that VWF pro-
cessing is associated with emphysema and exacerbations
and has prognostic value for assessing mortality risk. The
pathophysiological changes that occur in COPD are not
limited to the lungs, and the disease etiology is character-
ized by an increasing degree of systemic inflammation and
endothelial damage,6,15,17 also evident from previous stu-
dies finding VWF to be increased in COPD.8 Since VWF
processing is central to the primary response of wound
healing, biomarkers measuring the dynamic processing of
VWF could potentially aid in characterizing the pathophy-
siological changes in COPD. The activity of VWF can be
investigated by several methods, for example by the use of
ristocetin-dependent platelet aggregation,36 albeit this
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Figure 3 Increased VWF processing was associated with increased risk of mortality. (A) VWF-N and VWF-A levels were increased in subjects that died within a two-year
follow-up period (n=30) compared to survivors (n=910). (B) VWF biomarkers were dichotomized using AUROC analysis. Kaplan-Meier survival curves showed high
biomarker levels associated with decreased survival time. Data presented as median + 95% CI. **p<0.01, ***p<0.0001.
Langholm et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2020:15548
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 0
7-
Se
p-
20
20
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
method measures only VWF-processing indirectly and has
been reported to be less sensitive at low VWF levels.19
Here we apply the neo-epitope technology, specifically
targeting ADAMTS13-cleavage fragments of activated
VWF (VWF-A), together with newly endothelial released
VWF (VWF-N).
Biomarker levels of VWF-N and VWF-A were
increased in subjects with COPD compared to smoker
controls. Cigarette smokers with normal lung function
also experience pulmonary inflammation, but COPD sub-
jects are even more affected by smoking which gives them
an amplified inflammatory response7 that persists beyond
smoking cessation.17 Surprisingly we did not observe any
significant difference between COPD and non-smoker
controls, although when combining the two control groups
we did observe significantly lower levels of both markers.
This could partially be due to the limited amount of very
severe COPD participants (Table 1), although these results
could also be influenced by the difference in age, gender
and BMI between the groups, as hemostasis potential in
general is changed with aging,16 including VWF.12 hsCRP
data showed a significant difference between COPD and
both control groups, indicating an overall increase in
inflammatory state in COPD compared to controls. This
could mask any potential disease-related change in VWF
and therefore, these results indicate that the VWF-
processing biomarkers are not to be considered stand-
alone markers for disease diagnosis. Further studies should
seek to elucidate this potential bias.
We speculated that wound healing would be initiated to
a higher degree in symptomatic subjects which are known
to have a higher risk of exacerbations and mortality.42
Both biomarkers could discriminate symptomatic from
asymptomatic/mild COPD, underlining the increased
damage response in symptomatic disease as seen from
VWF-N levels, and suggesting ongoing active wound
healing reflected in the increased VWF-A levels. This is
in line with a previous study showing increased VWF
activity in symptomatic subjects, but interestingly no
change in total VWF was found in that study.8 We spec-
ulate that this is due to the endothelial release of VWF
being a more dynamic process, while total VWF reflect
a ratio between synthesis and degradation of VWF, which
might not be significantly changed in symptomatic disease.
Notably, no change was observed of either VWF biomar-
ker when dividing the cohort into GOLD severity groups.
Results similar to these have previously been reported,8
but could also be due to our cohort consisting of no mild
COPD (GOLD stage I) and only a limited number of
patients with very severe COPD (GOLD stage IV)
(Table 1). Further studies should address this in a study
representing the full range of COPD severities.
Table 2 Univariate Regression Analysis of Confounding Factors
of Mortality in COPD Subjects
Parameter Hazard Ratio
(95% CI)
P-value
Age 1.13 (1.06 to 1.21) 0.002
Sex 0.94 (0.45 to 1.96) 0.873
BMI 1.00 (0.94 to 1.06) 0.93
BODE 1.46 (0.97 to 2.06) 0.071
hsCRP 1.02 (1.01 to 1.03) <0.0001
FEV1 0.72 (0.35 to 1.46) 0.36
FEV1, % predicted 1.00 (0.98 to 1.02) 0.99
6-MWD 1.00 (0.99 to 1.00) 0.017
mMRC 1.50 (1.08 to 2.08) 0.017
Exacerbations, total 1.06 (0.98 to 1.15) 0.129
Prior exacerbation 0.99 (0.72 to 1.34) 0.927
Prior hospitalizations due to
exacerbations
1.52 (1.03 to 2.25) 0.037
Current smoker 5.72 (1.75 to 18.7) 0.004
Smoking, pack years 1.01 (1.00 to 1.02) 0.095
Notes: Total exacerbations; exacerbations during 3-years of study. Prior exacer-
bations; exacerbations 12 months prior to study start. Prior hospitalizations due to
exacerbations; severe exacerbations requiring hospitalization 12 months prior to
study start. Remaining data are baseline values.
Abbreviations: BMI, body mass index; BODE, Body mass index, airflow
Obstruction, Dyspnea and Exercise capacity; hsCRP, high-sensitivity C-reaction
protein; FEV1, Forced expiratory volume in one second; 6MWD, 6 min walking
distance; mMRC, modified medical research council (dyspnea scale).
Table 3 Multivariate Analyses of VWF Biomarkers as Predicters
of Mortality
Covariate Hazard Ratio P-value
VWF-N 1.21* (95% Cl 1.089;1.352) <0.001
VWF-A 1.26* (95% Cl 0.963;1.652) 0.002
VWF-N Model:
VWF-N > 6.7 4.05 (95% CI 1.72;9.53) 0.001
Age 1.08 (95% CI 1.01;1.17) 0.029
Former smoker 13.5 (95% CI 1.78;102.6) 0.012
hsCRP 1.02 (95% CI 1.01; 1.04) 0.001
VWF-A Model:
VWF-A > 9.7 2.88 (95% CI 1.23;6.74) 0.015
Age 1.14 (95% CI 1.05;1.24) 0.002
Former smoker 15.8 (95% CI 1.77;135.2) 0.014
hsCRP 1.02 (95% CI 1.01;1.04) 0.002
Notes: VWF models used pre-defined biomarker cutoffs (Youden index) from
Receiver operating characteristics (ROC) curve analysis of mortality. All models
and individual biomarkers were corrected for contributions from confounders (age,
6 min walking distance (6 MWD), mMRC, prior hospitalizations and current smok-
ing status). *Hazard ratios presented as standardized “HR per 1 SD increase”.
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Interestingly, we found that only VWF-N reflected the
more chronic progressive condition of emphysema, indi-
cating a sustained increase of VWF release into the circu-
lation. Emphysema is a result of chronic inflammatory
responses that induce slow progressive epithelial tissue
damage9 which is in agreement with VWF as a proposed
marker of endothelial dysfunction.18 To our knowledge, no
previous studies have shown VWF to be associated with
emphysema. The VWF-N biomarker specifically reflects
newly released VWF since it targets the C-terminal of the
VWF pro-peptide, which is only accessible when released
from the endothelia and thereby does not measure total
circulating VWF, a characteristic of (total) VWF-antigen
assays. The dynamic nature of this biomarker is also
underlined by studies showing that half-life of the pro-
peptide is significantly shorter than mature VWF (2 vs
12 hrs, respectively),10 thereby reflecting only recent or
ongoing endothelial damage.
VWF-A showed to be associated with the more acute
phenotype of exacerbations. This was also highlighted by
the fact that VWF-A had a better association with sympto-
matic disease than VWF-N. Previous studies have found
VWF-antigen but not VWF activity,8 to be increased in
exacerbating patients.34,35 The VWF-A assay targets
a neo-epitope within the A2-domain of VWF, which arises
from ADAMTS13-cleavage which is specific for active
VWF.28 This cleavage does not completely render VWF
inactive, but rather decreases VWF multimeric size to
regulate activity and dampens the coagulation response
to limit the risk of thrombosis.13 As previous exacerba-
tions are the best predictor for future exacerbations20 the
ability to identify patients at risk using biomarkers like
VWF-A might help prevent future events. It has been
suggested that endothelial cell response is modulated
when inflammation changes from acute to chronic,33
which might be reflected by VWF processing. We propose
that chronic inflammation and endothelial damage in
emphysema subjects induce a state of continuous VWF
synthesis and release from endothelial cells, but with
a lower rate of activation, while the acute damage which
arises during exacerbations results in an increased activa-
tion of VWF.
We suspected that the degenerative nature of endothelial
dysfunction and damage in COPD would be reflected in the
increased airflow limitation (FEV1). Although we saw signifi-
cantly decreased FEV1 levels in COPD (Table 1) this was not
associated with poorer outcome in this sub-cohort (Table 2),
which could indicate that airflow limitations might not be
a universal tool for clinical assessment.1 The limited number
of GOLD stage I and IV patients in our cohort (Table 1) could
possibly limit the association between FEV1 and outcome.
Interestingly, increased levels of VWF-N andVWF-A biomar-
kers were both associated with all-cause mortality and
decreased survival time. We have recently compared biomar-
kers of fibrinogen turnover to fibrinogen measured in the
ECLIPSE study.27 Plasma fibrinogen is currently the only
FDA approved prognostic marker for all-cause mortality in
COPD.26 Indeed, fibrinogen was found to be an independent
predictor of mortality, comparable to the results obtained for
the VWF biomarkers in this paper. We chose to compare the
VWF biomarkers to hsCRP as both they all reflect the state of
inflammation. Fibrinogen was excluded here although
Fibrinogen and VWF are associated with similar processes of
wound healing activation and platelet aggregation, since VWF
can also independently lead to platelet aggregation and subse-
quent wound healing activation during high shear stress con-
ditions known in COPD.5 We have discussed fibrinogen in
relation to wound healing in this cohort more thoroughly
elsewhere.27
To address the difference in age between the disease
and control groups we included this parameter in our
analyses. Interestingly, although age was found to be asso-
ciated with mortality, both VWF-N and VWF-A were
found to be independently associated with increased mor-
tality risk, when adjusting for confounders, including age.
This has previously been investigated in systemic inflam-
matory response syndrome where active VWF was found
to correlate with mortality, while total VWF was not.21
Collectively, these data suggest that lung endothelial
damage and initiation of the wound healing cascade in
COPD are associated with an increased mortality risk. As
COPD pathology manifests with tissue destruction and small
airway fibrosis it is not believed that anti–inflammatory treat-
ments will cure the disease, but early intervention might slow
down or halt progression entirely.7 Dynamic biomarkers of
VWF processing reflecting emphysema and exacerbation phe-
notypes might be a supplement to existing biomarkers to help
identify patientswith high risk of progression that could benefit
from anti–inflammatory treatments.
A limitation of our study is the relatively low mortality
rate (3%), hence a larger validation cohort is needed in
order to properly evaluate the prognostic value and help
define potential biomarker cut offs. A longitudinal study
setup would also be favoured over a cross-sectional study
to correlate progression and outcome with longitudinal
biomarker measurements. The effect of age and BMI on
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VWF levels should also be addressed in future studies
when addressing diagnostic potential of the biomarkers,
although adjusting for age in our study supports the prog-
nostic potential of the VWF biomarkers.
Conclusion
We demonstrate that differential processing of VWF is asso-
ciated with different pathophysiological aspects of COPD, as
we found that VWF-N reflected the chronic progressive
condition of emphysema, while VWF-A was associated
with acute exacerbations. These results generally support
other studies investigating total VWF, but also propose
a novel application for VWF biomarkers measuring dynamic
changes in VWF processing as accurate and precise bio-
chemicalmarkers to characterize the heterogeneity of COPD.
Data Sharing Statement
The datasets of used and/or analysed patient and biomar-
ker data are available upon reasonable request, and can be
acquired from the corresponding author.
Ethics Approval and Participant
Consent
The ECLIPSE study was conducted in compliance with
the Declaration of Helsinki and Good Clinical Practice
Guidelines, and has been approved by the relevant ethics
committees (see Supplementary Table 1). All participants
provided written informed consent prior to the study.
Acknowledgments
The authors acknowledge all participants, medical, nursing,
and technical staff involved in the ECLIPSE study. The study
was sponsored by GlaxoSmithKline; the Danish Agency for
Science, Technology and Innovation; and the Danish
Research Foundation. The study sponsors did not place any
restrictions with regard to statements made in the final paper.
Author Contributions
All authors contributed to data analysis, drafting and revis-
ing the article, gave final approval of the version to be
published, and agree to be accountable for all aspects of
the work.
Disclosure
RTS, BEM, and JV are part of the Evaluation of COPD
Longitudinally to Identify Surrogate Endpoints (ECLIPSE)
study investigators. LLL, SRR, JMBS, DJL, MAK and TMJ
are fulltime employees of Nordic Bioscience A/S. BEM is a
fulltime employee and shareholder of GlaxoSmithKline
(GSK). RTS is a former employee and current shareholder of
GSK. JV is supported by the National Institute of Health
Research Manchester Biomedical Research Centre (NIHR
Manchester BRC). JV reports personal fees from
AstraZeneca, grants from Boehringer-Ingelheim, personal
fees from Boehringer-Ingelheim, personal fees from Chiesi,
personal fees from GSK, and personal fees from Novartis,
outside the submitted work. The authors report no other con-
flicts of interest in this work.
References
1. Agusti A, Calverley PMA, Celli B, et al. Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)
investigators. Characterisation of COPD heterogeneity in the ECLIPSE
cohort. Respir Res. 2010;11:122. doi:10.1186/1465-9921-11-122
2. Alkady O, Fattouh M. Role of inflammatory biomarkers in COPD. In:
5.2 Monitoring Airway Disease. European Respiratory Society:PA1010.
2016. Available from: https://erj.ersjournals.com/content/48/suppl_60/
PA1010 . Accessed March 04, 2020.
3. André P, Denis CV, Ware J, et al. Platelets adhere to and translocate
on von Willebrand factor presented by endothelium in stimulated
veins. Blood. 2000;96:3322–3328. doi:10.1182/blood.V96.10.3322
4. Angelis N, Porpodis K, Zarogoulidis P, et al. Airway inflammation in
chronic obstructive pulmonary disease. J Thorac Dis. 2014;6(Suppl
1):S167–72. doi:10.3978/j.issn.2072-1439.2014.03.07
5. Barak OF, Mladinov S, Hoiland RL, et al. Disturbed blood flowworsens
endothelial dysfunction in moderate-severe chronic obstructive pulmon-
ary disease. Sci Rep. 2017;7. doi:10.1038/s41598-017-17249-6.
6. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the
lungs. PLoS Med. 2010;7:e1000220. doi:10.1371/journal.pmed.1000220
7. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmon-
ary disease. Nat Rev Drug Discov. 2013;12:543–559. doi:10.
1038/nrd4025
8. Bártholo TP, da Costa CH, Rufino R. Evaluation of von Willebrand
factor in COPD patients. J Bras Pneumol. 2014;40:373–379.
doi:10.1590/S1806-37132014000400004
9. Bihlet AR, Karsdal MA, Sand JMB, et al. Biomarkers of extra-
cellular matrix turnover are associated with emphysema and
eosinophilic-bronchitis in COPD. Respir Res. 2017;18:22.
doi:10.1186/s12931-017-0509-x
10. Borchiellini A, Fijnvandraat K, Ten Cate JW, et al. Quantitative
analysis of von Willebrand factor propeptide release in vivo: effect
of experimental endotoxemia and administration of 1-deamino-
8-D-arginine vasopressin in humans. Blood. 1996;88:2951–2958.
doi:10.1182/blood.V88.8.2951.bloodjournal8882951
11. Cockayne DA, Cheng DT, Waschki B, et al. Systemic biomarkers of
neutrophilic inflammation, tissue injury and repair in COPD patients
with differing levels of disease severity. PLoS One. 2012;7:e38629.
doi:10.1371/journal.pone.0038629
12. Coppola R, Mari D, Lattuada A, Franceschi C. Von Willebrand factor
in Italian centenarians. Haematologica. 2003;88:39–43.
13. Crawley JTB, de Groot R, Xiang Y, Luken BM, Lane DA, De
Groot R. Unravelling the scissile bond: how ADAMTS13 recognises
and cleaves von Willebrand factor. Blood. 2011;118:3212–3221.
doi:10.1182/blood-2011-02-306597
14. Donaldson G, Seemungal T, Bhowmik A, Wedzicha J. Relationship
between exacerbation frequency and lung function decline in chronic
obstructive pulmonary disease. Thorax. 2002;57:847–852. doi:10.11
36/thorax.57.10.847
Dovepress Langholm et al
International Journal of Chronic Obstructive Pulmonary Disease 2020:15 submit your manuscript | www.dovepress.com
DovePress
551
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 0
7-
Se
p-
20
20
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
15. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory
syndrome? Lancet. 2007;370:797–799. doi:10.1016/S0140-6736(07)
61383-X
16. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol.
2006;60:144–151. doi:10.1016/j.critrevonc.2006.06.004
17. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between
chronic obstructive pulmonary disease and systemic inflammation:
a systematic review and a meta-analysis. Thorax. 2004;59:574–580.
doi:10.1136/thx.2003.019588
18. Hogg JC. Pathophysiology of airflow limitation in chronic obstruc-
tive pulmonary disease. Lancet (London, England). 2004;364:70
9–721. doi:10.1016/S0140-6736(04)16900-6
19. Hulstein JJJ, de Groot PG, Silence K, Veyradier A, Fijnheer R,
Lenting PJ. A novel nanobody that detects the gain-of-function
phenotype of von Willebrand factor in ADAMTS13 deficiency and
von Willebrand disease type 2B. Blood. 2005;106:3035–3042.
doi:10.1182/blood-2005-03-1153
20. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in
chronic obstructive pulmonary disease. N Engl J Med. 2010;
363:1128–1138. doi:10.1056/NEJMoa0909883
21. Hyseni A, Kemperman H, de Lange DW, Kesecioglu J, de Groot PG,
Roest M. Active von Willebrand factor predicts 28-day mortality in
patients with systemic inflammatory response syndrome. Blood.
2014;123:2153–2156. doi:10.1182/blood-2013-08-508093
22. Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and
inflammation. J Thromb Haemost. 2017;15:1285–1294. doi:10.1111/
jth.2017.15.issue-7
23. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site
of platelet biogenesis and a reservoir for haematopoietic progenitors.
Nature. 2017;544:105–109. doi:10.1038/nature21706
24. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet
activation in patients with stable and acute exacerbation of COPD.
Thorax. 2011;66:769–774. doi:10.1136/thx.2010.157529
25. MacNee W. Pathogenesis of chronic obstructive pulmonary disease.
Proc Am Thorac Soc. 2005;2:258–66; discussion 290–1.
26. Mannino D, Tal-Singer R, Lomas D, et al. Plasma fibrinogen as
a biomarker for mortality and hospitalized exacerbations in people
with COPD. Chronic Obstr Pulm Dis J COPD Found. 2014;2:23–34.
doi:10.15326/jcopdf.2.1.2014.0138
27. Manon-Jensen T, Langholm LL, Rønnow SR, et al. End-product of
fibrinogen is elevated in emphysematous chronic obstructive pulmon-
ary disease and is predictive of mortality in the ECLIPSE cohort.
Respir Med. 2019;160:105814. doi:10.1016/j.rmed.2019.105814
28. Manon-Jensen T, Langholm LL, Sun S, et al. Initiation of the wound
healing cascade in inflammatory bowel disease: assessment of Von
Willebrand factor ADAMTS-13 processing and formation in crohn’s
disease. EC Gastroenterol Dig Syst. 2019;6:143–154.
29. van Mourik JA, Romani de Wit T. Von Willebrand factor propeptide
in vascular disorders. Thromb Haemost. 2001;86:164–171. doi:10.
1055/s-0037-1616214
30. Nightingale T, Cutler D. The secretion of von Willebrand factor from
endothelial cells; an increasingly complicated story. J Thromb
Haemost. 2013;11:192–201. doi:10.1111/jth.12225
31. Perotin J-M, Adam D, Vella-Boucaud J, et al. Delay of airway epithe-
lial wound repair in COPD is associated with airflow obstruction
severity. Respir Res. 2014;15:151. doi:10.1186/s12931-014-0151-9
32. Pimanda J, Hogg P. Control of von Willebrand factor multimer size
and implications for disease. Blood Rev. 2002;16:185–192. doi:10.
1016/S0268-960X(02)00017-6
33. Pober JS, Sessa WC. Evolving functions of endothelial cells in
inflammation. Nat Rev Immunol. 2007;7:803–815. doi:10.1038/
nri2171
34. Polatli M, Çakir A, Cildag O, Bolaman AZ, Yenisey C,
Yenicerioglu Y. Microalbuminuria, von Willebrand factor and fibri-
nogen levels as markers of the severity in COPD exacerbation.
J Thromb Thrombolysis. 2008;26:97–102. doi:10.1007/s11239-007-
0073-1
35. Polosa R, Malerba M, Cacciola RR, et al. Effect of acute exacerba-
tions on circulating endothelial, clotting and fibrinolytic markers in
COPD patients. Intern Emerg Med. 2013;8:567–574. doi:10.1007/
s11739-011-0636-1
36. Sagheer S, Rodgers S, Yacoub O, Dauer R, Mcrae S, Duncan E.
Comparison of von Willebrand factor (VWF) activity levels deter-
mined by HemosIL AcuStar assay and HemosIL LIA assay with
ristocetin cofactor assay by aggregometry. Haemophilia. 2016;22:
e200–e207. doi:10.1111/hae.2016.22.issue-3
37. Sand JMB, Knox AJ, Lange P, et al. Accelerated extracellular matrix
turnover during exacerbations of COPD. Respir Res. 2015;16:69.
doi:10.1186/s12931-015-0225-3
38. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfold-
ing triggers adhesion of von Willebrand factor fibers. Proc Natl Acad
Sci U S A. 2007;104:7899–7903. doi:10.1073/pnas.0608422104
39. Soler-Cataluña JJ, Martínez-García MÁ, Sánchez PR, Salcedo E,
Navarro M, Ochando R. Disease patients with chronic obstructive
pulmonary severe acute exacerbations and mortality in topic collec-
tions severe acute exacerbations and mortality in patients with
chronic obstructive pulmonary disease. Thorax. 2005;60:925–931.
doi:10.1136/thx.2005.040527
40. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD
longitudinally to identify predictive surrogate end-points
(ECLIPSE). Eur Respir J. 2008;31:869–873. doi:10.1183/090319
36.00111707
41. Vestbo J, Edwards LD, Scanlon PD, et al.; ECLIPSE Investigators.
Changes in forced expiratory volume in 1 second over time in COPD.
N Engl J Med. 2011;365:1184–1192. doi:10.1056/NEJMoa1105482
42. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diag-
nosis, management, and prevention of chronic obstructive pulmonary
disease GOLD executive summary. Am J Respir Crit Care Med.
2013;187:347–365. doi:10.1164/rccm.201204-0596PP
43. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell
Biol. 1990;6:217–246. doi:10.1146/annurev.cb.06.110190.001245
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
Publish your work in this journal
The International Journal of COPD is an international, peer-reviewed
journal of therapeutics and pharmacology focusing on concise rapid
reporting of clinical studies and reviews in COPD. Special focus is
given to the pathophysiological processes underlying the disease, inter-
vention programs, patient focused education, and self management
protocols. This journal is indexed on PubMed Central, MedLine
and CAS. The manuscript management system is completely online
and includes a very quick and fair peer-review system, which is
all easy to use. Visit http://www.dovepress.com/testimonials.php to
read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
Langholm et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2020:15552
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 0
7-
Se
p-
20
20
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
